← All trials
NCT03358719
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2018
- Primary completion
- Sep 13, 2019
- Completion date
- Sep 13, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- State University of New York, BuffaloLead sponsor
- Celldex TherapeuticsCollaborator
- State University of New York, BuffaloOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.